Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463971 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2019, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 6, 7, 1, 8, 2 and 1 respectively.

Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ventilator Associated Pneumonia (VAP) - Overview

Ventilator Associated Pneumonia (VAP) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Bioversys AG

Cumberland Pharmaceuticals Inc

CytaCoat AB

Destiny Pharma Plc

Dong-A Socio Holdings Co Ltd

Evaxion Biotech ApS

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics Plc

Nosopharm SAS

Polyphor AG

Shionogi & Co Ltd

Spero Therapeutics Inc

Tetraphase Pharmaceuticals Inc

VenatoRx Pharmaceuticals Inc

Wockhardt Ltd

Ventilator Associated Pneumonia (VAP) - Drug Profiles

(avibactam + aztreonam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(avibactam sodium + ceftazidime) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cefepime + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cefepime + VNRX-5133) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cefepime + zidebactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ceftolozane sulfate + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cilastatin sodium + imipenem + relebactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbekacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BV-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol sulfate tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBX-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eravacycline dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVXB-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfomycin disodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iclaprim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nacubactam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOSO-2G - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Panaecin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

panobacumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-7001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qn-2251 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections and Ventilator Associated Pneumonia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvratoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tedizolid phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telavancin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tosatoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ventilator Associated Pneumonia (VAP) - Dormant Projects

Ventilator Associated Pneumonia (VAP) - Discontinued Products

Ventilator Associated Pneumonia (VAP) - Product Development Milestones

Featured News & Press Releases

Oct 15, 2019: New study reveals superiority of Vibativ over Vancomycin in select patients with Bacterial Pneumonia

Oct 02, 2019: Shionogi reports positive results from Cefiderocol phase III study in adults with pneumonia caused by gram-negative pathogens

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463971 | GMDHC11406IDB

Number of Pages

169

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
28-02-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.